Chronic Lymphocytic Leukemia Sales

Chronic Lymphocytic Leukemia Sales Market Outlook

As of 2023, the global Chronic Lymphocytic Leukemia (CLL) sales market is projected to reach approximately USD 9.3 billion, with an anticipated compound annual growth rate (CAGR) of around 7.4% from 2025 to 2035. The growth of this market can be attributed to several factors, including the increasing incidence rates of CLL worldwide, advancements in targeted therapies, and the growing awareness and availability of treatment options. Furthermore, the introduction of novel drugs, especially those targeting specific genetic abnormalities associated with CLL, is also expected to contribute significantly to market expansion. The aging population, which is more susceptible to CLL, coupled with improved diagnostic techniques, is also driving the growth upward. In addition, the rising investment in research and development aimed at finding more effective therapeutic options for CLL is likely to enhance market dynamics.

Growth Factor of the Market

The growth of the Chronic Lymphocytic Leukemia sales market is primarily driven by an increasing number of diagnosed cases globally, which is expected to surge due to heightened awareness and better screening processes. The introduction of innovative therapies, particularly targeted and immunotherapies, is revolutionizing treatment paradigms and thus fueling market growth. For instance, advancements in the understanding of molecular biology have led to the development of drugs that can specifically target the pathways involved in CLL progression. Additionally, the expansion of healthcare infrastructure in developing regions is facilitating better access to these medications, thereby positively impacting sales. Furthermore, ongoing clinical trials and research initiatives are paving the way for new and effective treatment options, which are likely to further stimulate market growth. Lastly, patient advocacy groups are increasingly influencing treatment decisions, pushing for better access and affordability of CLL therapies.

Key Highlights of the Market

• Projected global market size of approximately USD 9.3 billion by 2025.
• Anticipated CAGR of around 7.4% from 2025 to 2035.
• Growing incidence of CLL and advancements in diagnostic techniques.
• Expansion of targeted therapies and immunotherapies.
• Increasing healthcare expenditure and patient advocacy initiatives.

By Product Type

Chemotherapy Drugs:

Chemotherapy drugs have traditionally been one of the mainstays in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs work by targeting rapidly dividing cells, thereby inhibiting the growth of cancerous cells in the bloodstream. The use of chemotherapy, although effective, is often associated with a range of side effects, including fatigue, nausea, and immunosuppression. Nevertheless, these drugs continue to play a critical role, especially in younger patients or those with aggressive forms of CLL, where they can induce remission. With the advent of combination therapies that integrate chemotherapy with newer targeted therapies, the efficacy of these drugs is further enhanced, driving their sales in the market.

Targeted Therapy Drugs:

Targeted therapy drugs represent a significant advancement in the treatment of CLL. These drugs are designed to specifically target the molecular abnormalities that drive the growth of leukemia cells, leading to improved outcomes and reduced side effects. Agents such as Bruton's tyrosine kinase (BTK) inhibitors exemplify this trend, demonstrating substantial efficacy in clinical trials and real-world applications. The increasing preference for these therapies among healthcare providers and patients alike is expected to boost their market share significantly. Moreover, ongoing research and the development of next-generation targeted therapies are set to further enhance their appeal, making them a cornerstone of modern CLL treatment.

Immunotherapy Drugs:

Immunotherapy drugs are emerging as a revolutionary treatment avenue in the management of Chronic Lymphocytic Leukemia. This class of drugs works by stimulating the body’s immune system to recognize and fight CLL cells more effectively. Approaches such as CAR T-cell therapy have shown promising results in clinical trials, leading to durable remissions in certain patient populations. The growing acceptance of immunotherapy as a viable treatment option is leading to increased investment in research and development, which is expected to result in more products entering the market. As healthcare professionals become more familiar with these therapies and their benefits, the demand for immunotherapy drugs in the CLL market is likely to rise significantly.

Monoclonal Antibodies:

Monoclonal antibodies have transformed the landscape of CLL treatment by providing targeted options that improve the specificity of therapies. These antibodies work by recognizing specific antigens on the surface of CLL cells and marking them for destruction by the immune system. Drugs such as Rituximab and Obinutuzumab are prime examples that have gained approval for use in CLL. The effectiveness of these drugs, coupled with their relatively favorable safety profile compared to traditional chemotherapy, has led to their increasing utilization in clinical practice. The anticipated growth in the monoclonal antibody segment is fueled by the ongoing development of second-generation antibodies and combination regimens that promise enhanced efficacy.

Others:

The 'Others' category encompasses various treatment modalities and experimental therapies currently under research for Chronic Lymphocytic Leukemia. This includes novel agents and compounds that may not yet have received widespread acceptance or approval but hold potential for future use. As the field of oncology continues to evolve, these emerging treatments could significantly impact the CLL landscape. The interest in these alternative therapies is driven by a growing need for personalized medicine approaches and the desire for therapies that minimize side effects and improve patient quality of life. The exploration of combination therapies that include agents from this category is expected to drive further growth in the market over the coming years.

By Application

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of medications for Chronic Lymphocytic Leukemia, particularly in providing comprehensive care to patients undergoing treatment. These pharmacies are equipped to offer personalized medication management and patient education, which are essential in managing complex therapy regimens. The growing trend of inpatient treatment for CLL, especially in cases requiring intensive therapeutic interventions, is driving the demand for drugs dispensed through hospital pharmacies. Additionally, hospitals are increasingly becoming centers for the administration of advanced therapies such as immunotherapies and targeted treatments, reinforcing their significance in the CLL market.

Retail Pharmacies:

Retail pharmacies are vital in ensuring that patients with Chronic Lymphocytic Leukemia have access to their medications outside the hospital setting. These pharmacies provide convenience and accessibility for patients, allowing for easier management of ongoing therapy. The rise of chronic disease management programs and patient-centered care initiatives is driving greater collaboration between retail pharmacies and healthcare providers. As patients often prefer to fill prescriptions at local pharmacies, the retail sector is likely to see an increase in the volume of CLL-related medications dispensed, particularly as awareness of CLL grows and more patients seek treatment options.

Online Pharmacies:

Online pharmacies have emerged as a significant channel for the distribution of Chronic Lymphocytic Leukemia medications, driven by the convenience they offer patients. The increasing trend of e-commerce in healthcare is reshaping how patients access their prescriptions. Online pharmacies often provide competitive pricing and the ability to refill prescriptions quickly, which is particularly beneficial for those requiring long-term therapy. The COVID-19 pandemic accelerated the adoption of online pharmacy services, and this trend is expected to continue as patients prioritize safety and convenience. As regulations around telehealth and e-pharmacy evolve, this distribution channel is poised for considerable growth in the CLL market.

Others:

The 'Others' segment in the application category includes various channels through which CLL medications may be distributed, such as specialty pharmacies and physician offices. Specialty pharmacies, in particular, are designed to handle complex therapies that often require special handling, storage, or monitoring. They are an essential part of the treatment continuum for CLL patients, offering tailored services that ensure adherence to therapy and minimize complications. As the complexity of CLL treatment increases with the introduction of novel therapies, the importance of these alternative distribution channels will likely grow, contributing to an expanding market.

By Distribution Channel

Online Stores:

The rise of online stores as a distribution channel for Chronic Lymphocytic Leukemia medications has transformed how patients access their treatments. The convenience of ordering medications from home and having them delivered directly to patients' doors is a significant advantage, particularly for those who may have mobility issues or live in remote areas. Online pharmacies often provide additional services, such as medication reminders and consultation options, which enhance patient adherence to prescribed regimens. The market for online pharmacies is expected to grow as more patients become comfortable with e-commerce and as digital health initiatives continue to expand. Increased regulatory support and the establishment of secure online platforms will also bolster this channel’s growth.

Supermarkets/Hypermarkets:

Supermarkets and hypermarkets are becoming increasingly popular venues for the distribution of Chronic Lymphocytic Leukemia medications, especially over-the-counter supplements and supportive care products. These retail giants often provide a wide range of health products and services, making them a one-stop shop for patients. The convenience of being able to pick up medications while grocery shopping appeals to many consumers. Additionally, supermarkets are increasingly collaborating with pharmacies to offer prescription services on-site, thus enhancing the accessibility of medications for CLL. This trend is expected to continue, as patients seek convenience and integrated health services.

Specialty Stores:

Specialty stores, particularly those focused on health and wellness, have become important players in distributing Chronic Lymphocytic Leukemia treatments and supportive care products. These stores often provide a curated selection of products that cater to specific patient needs, including dietary supplements, nutritional products, and medical supplies that support CLL management. The growing consumer awareness regarding health and nutrition is expected to drive demand within specialty stores, as patients seek comprehensive solutions to manage their condition. Moreover, these stores often employ knowledgeable staff who can provide valuable support and guidance to patients navigating their treatment options.

Others:

The 'Others' distribution channel encompasses various less conventional outlets through which CLL medications may be accessed. This includes clinics, direct-to-consumer models, and non-traditional retail environments. These channels are becoming increasingly relevant as healthcare evolves and patients seek diverse options for accessing their treatments. Direct-to-consumer models, in particular, are gaining traction as pharmaceutical companies explore innovative ways to reach patients. The diversification of distribution channels reflects the changing landscape of healthcare access and the need for personalized care solutions for CLL patients.

By Drug Type

BTK Inhibitors:

Bruton's Tyrosine Kinase (BTK) inhibitors represent a breakthrough in the treatment of Chronic Lymphocytic Leukemia, offering a targeted approach that has shown significant clinical efficacy. These drugs work by blocking the signaling pathways that promote the survival and proliferation of malignant B-cells. With agents like Ibrutinib gaining prominence in clinical practice, BTK inhibitors are quickly becoming first-line therapies for CLL patients. The ongoing research into combinations with other therapeutic modalities is likely to expand their indications and enhance their market presence further. As healthcare providers increasingly adopt these therapies, the demand for BTK inhibitors is expected to rise steadily, driving their sales in the CLL market.

PI3K Inhibitors:

Phosphoinositide 3-kinase (PI3K) inhibitors are another class of targeted therapies that have shown promise in treating Chronic Lymphocytic Leukemia. These agents interfere with the PI3K signaling pathway, which is crucial for the survival and proliferation of cancer cells. With drugs like Idelalisib leading the charge in this category, PI3K inhibitors are gaining traction among clinicians. The ability to use these drugs in combination with other therapies further enhances their potential market share. As clinical data continues to emerge demonstrating their effectiveness in various patient populations, PI3K inhibitors are likely to become increasingly integrated into CLL treatment regimens.

CD20 Monoclonal Antibodies:

CD20 monoclonal antibodies, such as Rituximab and Obinutuzumab, have revolutionized the landscape of Chronic Lymphocytic Leukemia treatment by offering a targeted approach that enhances the immune response against malignant B-cells. These therapies are often used in combination with other treatments, showcasing their ability to improve patient outcomes significantly. The growing body of evidence supporting the use of CD20 monoclonal antibodies in various therapeutic settings is likely to drive continued interest and investment in this category. As the understanding of CLL biology evolves, the potential for new combinations and novel applications for CD20 monoclonal antibodies will further enhance their market presence.

Others:

The 'Others' category within drug types encompasses various emerging therapies and investigational agents that are not yet widely recognized in the CLL treatment landscape. This includes emerging small molecules, innovative biologics, and novel combination therapies that are currently in clinical trials. As research progresses and new data becomes available, these therapies may present substantial opportunities for growth in the CLL market. The commitment of pharmaceutical companies to explore uncharted territories in drug development suggests that the 'Others' category could play a crucial role in shaping the future of CLL treatment, especially as personalized medicine approaches become more prevalent.

By Region

The regional analysis of the Chronic Lymphocytic Leukemia sales market indicates that North America holds a dominant share, accounting for approximately 40% of the global market in 2023. This is primarily due to advanced healthcare infrastructure, high healthcare expenditure, and the presence of key pharmaceutical companies engaged in the development of innovative therapies. The North American market is anticipated to grow at a CAGR of around 8.2% through 2035, driven by the increasing prevalence of CLL and the ongoing introduction of novel drugs and treatment paradigms. The region’s robust research environment further supports the evolution of CLL therapies, ensuring continued growth in market share.

Europe holds the second-largest share of the Chronic Lymphocytic Leukemia sales market, contributing about 30% of the total market size. The European market is characterized by a growing focus on personalized medicine and the adoption of targeted therapies. As regulatory frameworks become more supportive of innovation in healthcare, Europe is expected to witness a CAGR of approximately 6.5% over the forecast period. The increasing collaboration between healthcare providers and pharmaceutical companies in Europe is driving advancements in treatment options, further enhancing the market. Meanwhile, Asia Pacific is emerging as a significant player, with rapid growth anticipated due to rising healthcare investments and improving access to therapies.

Opportunities

There are several burgeoning opportunities within the Chronic Lymphocytic Leukemia sales market that stakeholders should capitalize on. First, the rising prevalence of CLL globally presents a significant market opportunity for pharmaceutical companies to innovate and develop new therapies tailored to specific patient populations. With advancements in genetic testing and biomarkers, the ability to personalize treatment regimens will likely lead to improved patient outcomes and adherence, ultimately driving sales. Furthermore, as the healthcare landscape evolves, there is an increasing emphasis on integrated care, providing an avenue for companies to partner with healthcare providers for comprehensive treatment solutions. Coupled with the growth of digital health initiatives, including telemedicine and mobile health applications, there is a unique opportunity for companies to engage patients and streamline treatment delivery, enhancing overall market potential.

Moreover, the expansion of healthcare access in emerging markets represents a significant opportunity for growth within the CLL sales market. As countries in regions such as Asia Pacific and Latin America invest in their healthcare infrastructure and adopt supportive policies for drug access, pharmaceutical companies have the chance to introduce their products to new patient populations. Additionally, the rising interest in clinical trials and research collaborations can lead to the discovery of innovative therapies that address unmet medical needs in CLL. This strategic approach to expanding into new markets will be crucial for organizations aiming to maintain a competitive advantage and drive sustained growth in the coming years.

Threats

Despite the promising outlook for the Chronic Lymphocytic Leukemia sales market, several threats could impede progress. One of the primary concerns is the potential for market saturation, particularly as more therapies enter the landscape. With increasing competition, pharmaceutical companies may face pricing pressures and the need to demonstrate superior efficacy or safety profiles to differentiate their products. Furthermore, the risk of regulatory hurdles and delays in drug approvals can hinder the timely introduction of new therapies, impacting sales projections. The dynamic nature of healthcare policies, including changes in reimbursement frameworks, could also present challenges for market players as they navigate the complexities of drug pricing and access.

Another critical threat to the market is the rising incidence of treatment resistance, particularly with targeted therapies such as BTK inhibitors. As patients undergo long-term treatment, the likelihood of developing resistance to existing therapies increases, necessitating the constant development of new agents and combination strategies. This ongoing challenge can strain resources and impact the profitability of existing products in the market. Additionally, the economic landscape and potential global recessions may influence healthcare spending, leading to reduced access for patients, especially in emerging markets. Stakeholders in the CLL market must remain vigilant and adaptable to navigate these threats successfully.

Competitor Outlook

• AbbVie Inc.
• Roche Holding AG
• Johnson & Johnson
• AstraZeneca PLC
• Novartis AG
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Amgen Inc.
• Merck & Co., Inc.
• Celgene Corporation
• Incyte Corporation
• Seattle Genetics, Inc.
• Karyopharm Therapeutics Inc.

The competitive landscape of the Chronic Lymphocytic Leukemia sales market is characterized by a mix of established pharmaceutical giants and emerging biotech firms. Companies like AbbVie, Roche, and Johnson & Johnson dominate the market, leveraging their extensive research capabilities and established distribution networks to maintain leadership positions. These companies continually invest in research and development to discover and bring novel therapies to market, enhancing their product portfolios. Additionally, strategic collaborations and partnerships with academic institutions and research organizations are common within this sector, allowing for the development of innovative treatment options that address unmet medical needs in CLL patients.

Moreover, the competition extends beyond just drug manufacturing; it encompasses various aspects, including patient support programs, educational initiatives, and marketing strategies to engage healthcare providers. The emergence of biosimilars and generics is further intensifying competition, as these alternatives offer cost-effective treatment options for patients and healthcare providers. As the market evolves, companies must remain agile and responsive to changing dynamics, ensuring they adapt their strategies to maintain a competitive edge. With an increasing focus on personalized medicine, organizations that successfully harness data analytics and patient insights will have a distinct advantage in the Chronic Lymphocytic Leukemia market.

Key players in the market, such as Gilead Sciences, Novartis, and Bristol-Myers Squibb, are focusing on expanding their therapeutic pipelines through acquisitions and partnerships. For instance, Gilead's acquisition of Kite Pharma enabled it to strengthen its position in the cell therapy segment, specifically CAR T-cell therapies for cancers, including CLL. Similarly, Novartis is actively pursuing research in innovative therapies, looking to enhance its offerings in the oncology space. As these companies continue to push the boundaries of research and product development, the competitive landscape of the Chronic Lymphocytic Leukemia sales market is expected to become increasingly dynamic.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca PLC
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Incyte Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gilead Sciences, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Seattle Genetics, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Karyopharm Therapeutics Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Chronic Lymphocytic Leukemia Sales Market, By Application
    • 6.1.1 Hospital Pharmacies
    • 6.1.2 Retail Pharmacies
    • 6.1.3 Online Pharmacies
    • 6.1.4 Others
  • 6.2 Chronic Lymphocytic Leukemia Sales Market, By Product Type
    • 6.2.1 Chemotherapy Drugs
    • 6.2.2 Targeted Therapy Drugs
    • 6.2.3 Immunotherapy Drugs
    • 6.2.4 Monoclonal Antibodies
    • 6.2.5 Others
  • 6.3 Chronic Lymphocytic Leukemia Sales Market, By Distribution Channel
    • 6.3.1 Online Stores
    • 6.3.2 Supermarkets/Hypermarkets
    • 6.3.3 Specialty Stores
    • 6.3.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Chronic Lymphocytic Leukemia Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Chronic Lymphocytic Leukemia Sales market is categorized based on

By Product Type

• Chemotherapy Drugs
• Targeted Therapy Drugs
• Immunotherapy Drugs
• Monoclonal Antibodies
• Others

By Application

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Distribution Channel

• Online Stores
• Supermarkets/Hypermarkets
• Specialty Stores
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Roche Holding AG
• Johnson & Johnson
• AstraZeneca PLC
• Novartis AG
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Amgen Inc.
• Merck & Co., Inc.
• Celgene Corporation
• Incyte Corporation
• Seattle Genetics, Inc.
• Karyopharm Therapeutics Inc.